Table 4 Comparison of intervention and placebo groups in terms of side effects
| Â | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
No | Yes | OR (95% CI) | P-value | OR (95% CI) | P-value | |
Group | ||||||
 Active | 23 (69.7%) | 10 (30.3%) | 1.81 (0.57,5.78) | 0.315 | 1.97 (0.58,6.69) | 0.279 |
 Placebo | 25 (80.6%) | 6 (19.4%) | Reference | Reference | ||
Sex | ||||||
 Female | 34 (79.1%) | 9 (20.9%) | Reference | 0.286 | Reference | 0.155 |
 Male | 14 (66.7%) | 7 (33.7%) | 1.89 (0.59,6.07) | 2.81 (0.68,11.65) | ||
Marital Status | ||||||
 Single | 17 (70.8%) | 7 (29.2%) | 1.42 (0.45,4.86) | 0.552 | 0.48 (0.18,3.99) | 0.823 |
 Married | 31 (77.5%) | 9 (22.5%) | Reference | Reference | ||
Duration of Migraine | ||||||
 ≤2 years | 26 (72.2%) | 10 (27.8%) | 1.41 (0.44,4.50) | 0.562 | 0.94 (0.25,3.51) | 0.992 |
 > 2 years | 22 (78.6%) | 6 (21.4%) | Reference | Reference | ||
Age (mean ± SD) | 37.29 ± 9.42 | 33.81 ± 8.89 | 0.96 (0.89,1.02) | 0.20 | 0.97 (0.87,1.07) | 0.494 |
BMI (mean ± SD) | 24.25 ± 3.03 | 23.14 ± 2.99 | 0.88 (0.72,1.08) | 0.21 | 0.88 (0.68,1.16) | 0.369 |